Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Iovance Biotherapeutics ( (IOVA) ) just unveiled an announcement.
On January 9, 2026, Iovance Biotherapeutics updated its corporate presentation, indicating that it expected to meet its previously disclosed full-year 2025 revenue guidance of $250 million to $300 million in the first full calendar year of Amtagvi sales. The presentation highlighted that total revenue since the first quarter of 2024 had reached about $340 million as of September 30, 2025, with approximately $307 million in cash on hand, more than 85 treatment centers in the U.S. and Canada and multiple global markets engaged, and improving gross margins following organizational streamlining. Iovance emphasized its leadership in TIL-based cell therapy, the commercial momentum of Amtagvi in advanced melanoma with real-world response rates around 50%, and the potential for substantial future growth driven by ongoing registration-directed trials in metastatic non-small cell lung cancer and other solid tumors, positioning the company as a key player in next-generation oncology cell therapies.
The most recent analyst rating on (IOVA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.
Spark’s Take on IOVA Stock
According to Spark, TipRanks’ AI Analyst, IOVA is a Neutral.
The score is held back primarily by weak financial performance (large losses and negative cash flows). It is supported by constructive technical momentum and a positive earnings-call outlook (improving margins, reiterated revenue guidance, and favorable clinical/commercial progress). Valuation remains pressured by losses and the absence of a dividend.
To see Spark’s full report on IOVA stock, click here.
More about Iovance Biotherapeutics
Iovance Biotherapeutics is a biotechnology company focused on developing and commercializing tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors, with its lead product Amtagvi approved for advanced melanoma in the U.S. and Canada. The company operates a global manufacturing and supply chain network, reports more than 1,000 patients treated with its commercial and clinical TIL products, and is expanding its solid tumor portfolio across melanoma, non-small cell lung cancer, endometrial cancer and next-generation engineered TIL programs, supported by a modular manufacturing facility and global field teams.
Average Trading Volume: 14,528,476
Technical Sentiment Signal: Sell
Current Market Cap: $1.1B
See more data about IOVA stock on TipRanks’ Stock Analysis page.